Conference Proceedings

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

Shom Goel, Joyce O'Shaughnessy, Antoinette R Tan, Boris Milev Krastev, Hope S Rugo, Philippe Georges Aftimos, Denise A Yardley, Andric Zoran, Curt Douglas Wolfgang, Jessica Sorrentino, Wenli Tao, Andrew Paul Beelen, Rajesh K Malik, Sarika Jain

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

Abstract

TPS1107 Background: Trilaciclib is an intravenous (IV), highly potent and selective, reversible cyclin-dependent kinase (CDK) 4/6 inhibitor that protects hematopoietic stem and progenitor cells during chemotherapy (myeloprotection) and may directly enhance antitumor immunity (anticancer efficacy). In a randomized phase 2 trial of trilaciclib administered prior to gemcitabine and carboplatin (GC) versus GC alone in advanced/metastatic triple-negative breast cancer (mTNBC), although the primary endpoint of myeloprotection was not met, the addition of trilaciclib resulted in a substantial improvement in median overall survival (OS; 19.8 months with trilaciclib vs 12.6 months with placebo, haza..

View full abstract